Search

Your search keyword '"François, Eric"' showing total 238 results
Start Over Author "François, Eric" Language english
238 results on '"François, Eric"'

3. Short course radiotherapy versus radiochemotherapy for locally advanced rectal cancers in the elderly (UNICANCER PRODIGE 42/GERICO 12 study): Quality of life and comprehensive geriatric assessment

Author

François, Eric, Magné, Nicolas, Boulahssass, Rabia, Ronchin, Philippe, Huguenet, Virginie, De Lavigerie, Blandine, Nouhaud, Elodie, Cattenoz, Catherine, Martel-Lafay, Isabelle, Terret, Catherine, Artru, Pascal, Clavere, Pierre, Tchalla, Achille, Vendrely, Véronique, Duc, Sophie, Boige, Valérie, De Sousa Carvalho, Nicolas, Gal, Jocelyn, and De Bari, Berardino

Published
2024
Full Text
View/download PDF

9. What is the optimal treatment for T1N0 anal squamous cell carcinoma? Analysis of current practices in the prospective French FFCD ANABASE cohort

Author

Bacci, Manon, Quero, Laurent, Barbier, Emilie, Parrot, Laurène, Juguet, Frédéric, Pommier, Pascal, Bazire, Louis, Etienney, Isabelle, Baba-Hamed, Nabil, Spindler, Lucas, François, Eric, Ronchin, Philippe, Campo, Eleonor Rivin Del, Lemanski, Claire, Lièvre, Astrid, Siproudhis, Laurent, Abramowitz, Laurent, Lepage, Côme, and Vendrely, Véronique

Published
2021
Full Text
View/download PDF

10. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial

Author

Borg, Christophe, Etienne, Pierre-Luc, Rio, Emmanuel, Mesgouez-Nebout, Nathalie, François, Éric, Vendrely, Véronique, Conroy, Thierry, Artignan, Xavier, Bouché, Olivier, Gargot, Dany, Boige, Valérie, Bonichon-Lamichhane, Nathalie, Louvet, Christophe, Morand, Clotilde, de la Fouchardière, Christelle, Ronchin, Philippe, Seitz, Jean-François, Corbinais, Stéphane, Maillard, Emmanuel, Noirclerc, Monique, El Hajbi, Farid, Villing, Anne-Laure, Bécouarn, Yves, Foong Fat Lam Kam Sang, Lam, Artru, Pascal, Bachet, Jean-Baptiste, Hocine, Fayçal, Ligeza-Poisson, Catherine, Vautravers, Claire, Ben Abdelghani, Meher, Aparicio, Thomas, Desot, Elise, Marquis, Isabelle, Bosset, Jean-François, Lamfichekh, Najib, Juzyna, Béata, Jouffroy-Zeller, Claire, Rullier, Eric, Marchal, Frédéric, Gourgou, Sophie, and Castan, Florence

Published
2021
Full Text
View/download PDF

13. Sorafenib Plus Irinotecan Combination in Patients With RAS-mutated Metastatic Colorectal Cancer Refractory To Standard Combined Chemotherapies: A Multicenter, Randomized Phase 2 Trial (NEXIRI-2/PRODIGE 27)

Author

Samalin, Emmanuelle, Fouchardière, Christelle de la, Thézenas, Simon, Boige, Valérie, Senellart, Hélène, Guimbaud, Rosine, Taïeb, Julien, François, Eric, Galais, Marie-Pierre, Lièvre, Astrid, Seitz, Jean-François, Metges, Jean-Philippe, Bouché, Olivier, Boissière-Michot, Florence, Lopez-Crapez, Evelyne, Bibeau, Frédéric, Ho-Pun-Cheung, Alexandre, Ychou, Marc, Adenis, Antoine, Di Fiore, Frédéric, and Mazard, Thibault

Published
2020
Full Text
View/download PDF

21. Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature: An Ancillary Study of the PRODIGE-24/CCTG PA6 Clinical Trial.

Author

Nicolle, Rémy, Bachet, Jean-Baptiste, Harlé, Alexandre, Iovanna, Juan, Hammel, Pascal, Rebours, Vinciane, Turpin, Anthony, Ben Abdelghani, Meher, Wei, Alice, Mitry, Emmanuel, Lopez, Anthony, Biagi, James, François, Eric, Artru, Pascal, Lambert, Aurélien, Renouf, Daniel J., Monard, Laure, Mauduit, Marjorie, Dusetti, Nelson, and Conroy, Thierry

Published
2024
Full Text
View/download PDF

22. Examining the dynamics of illiquidity risks within the phases of the business cycle

Author

François-Eric Racicot, William F. Rentz, Alfred Kahl, and Olivier Mesly

Subjects
Finance, HG1-9999
Abstract

The Fama-French (FF) five-factor model is cast into a dynamic setting to capture the impact of illiquidity over the phases of the business cycle on the returns of the passive FF twelve sector portfolios. We use two dynamic approaches, Kalman filtering and a recursive/rolling robust instrumental variables (IV) algorithm cast into a GMM framework, to determine time-varying alpha and beta estimates. Our principal result is that the Kalman filter approach supports the hypothesis that illiquidity is an important risk factor in a dynamic context. However, the only factor found to matter in the dynamic GMM approach is the market risk premium. Nevertheless, illiquidity may be prescient with respect to financial crises. Keywords: Illiquidity, Fama-French five-factor model, Kalman filter, Robust IV algorithm, JEL Classification: C58, G12

Published
2019
Full Text
View/download PDF

24. Predicting early death in older adults with cancer

Author

Boulahssass, Rabia, Gonfrier, Sebastien, Ferrero, Jean-Marc, Sanchez, Marine, Mari, Véronique, Moranne, Olivier, Rambaud, Cyrielle, Auben, Francine, Hannoun levi, Jean-Michel, Bereder, Jean-Marc, Bereder, Isabelle, Baque, Patrick, Turpin, Jean Michel, Frin, Anne-Claire, Ouvrier, Delphine, Borchiellini, Delphine, Largillier, Remy, Sacco, Guillaume, Delotte, Jerome, Arlaud, Cyprien, Benchimol, Daniel, Durand, Matthieu, Evesque, Ludovic, Mahamat, Abakar, Poissonnet, Gilles, Mouroux, Jérôme, Barriere, Jérôme, Benizri, Emmanuel, Piche, Thierry, Guigay, Joel, Francois, Eric, and Guerin, Olivier

Published
2018
Full Text
View/download PDF

25. Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials

Author

Adenis, A., Alessio, A., Aouakli, A., Azzedine, A., Bedjaoui, A., Bidault, A., Blanchi, A., Botton, A., Cadier-Lagnes, A., Fatisse, A., Gagnaire, A., Gilbert, A., Gueye, A., Hollebecque, A., Lemaire, A., Mahamat, A., Marre, A., Patenotte, A., Rotenberg, A., Roussel, A., Thirot-Bidault, A., Votte, A., Weber, A., Zaanan, A., Dupont-Gossart, A.C., Villing, A.L., Queuniet, A.M., Coudert, B., Denis, B., Garcia, B., Lafforgue, B., Landi, B., Leduc, B., Linot, B., Paillot, B., Rhein, B., Winkfield, B., Barberis, C., Becht, C., Belletier, C., Berger, C., Bineau, C., Borel, C., Brezault, C., Buffet, C., Cornila, C., Couffon, C., De La Fouchardière, C., Giraud, C., Lecaille, C., Lepere, C., Lobry, C., Locher, C., Lombard-Bohas, C., Paoletti, C., Platini, C., Rebischung, C., Sarda, C., Vilain, C., Briac-Levaché, C., Auby, D., Baudet-Klepping, D., Bechade, D., Besson, D., Cleau, D., Festin, D., Gargot, D., Genet, D., Goldfain, D., Luet, D., Malka, D., Peré-Vergé, D., Pillon, D., Sevin-Robiche, D., Smith, D., Soubrane, D., Tougeron, D., Zylberait, D., Carola, E., Cuillerier, E., Dorval Danquechin, E., Echinard, E., Janssen, E., Maillard, E., Mitry, E., Norguet-Monnereau, E., Suc, E., Terrebonne, E., Zrihen, E., Pariente, E.A., Almaric, F., Audemar, F., Bonnetain, F., Desseigne, F., Dewaele, F., Di Fiore, F., Ghiringhelli, F., Husseini, F., Khemissa, F., Kikolski, F., Morvan, F., Petit-Laurent, F., Riot, F., Subtil, F., Zerouala-Boussaha, F., Caroli-Bosc, F.X., Boilleau-Jolimoy, G., Bordes, G., Cavaglione, G., Coulanjon, G., Deplanque, G., Gatineau-Saillant, G., Goujon, G., Medinger, G., Roquin, G., Brixi-Benmansour, H., Castanie, H., Lacroix, H., Maechel, H., Perrier, H., Salloum, H., Senellart, H., Baumgaertner, I., Cumin, I., Graber, I., Trouilloud, I., Boutin, J., Butel, J., Charneau, J., Cretin, J., Dauba, J., Deguiral, J., Egreteau, J., Ezenfis, J., Forestier, J., Goineau, J., Lacourt, J., Lafon, J., Martin, J., Meunier, J., Moreau, J., Provencal, J., Taieb, J., Thaury, J., Tuaillon, J., Vergniol, J., Villand, J., Vincent, J., Volet, J., Bachet, J.B., Barbare, J.C., Souquet, J.C., Grangé, J.D., Dor, J.F., Paitel, J.F., Jouve, J.L., Raoul, J.L., Cheula, J.M., Gornet, J.M., Sabate, J.M., Vantelon, J.M., Vaillant, J.N., Aucouturier, J.P., Barbieux, J.P., Herr, J.P., Lafargue, J.P., Lagasse, J.P., Latrive, J.P., Plachot, J.P., Ramain, J.P., Robin, J.P., Spano, J.P., Douillard, J.Y., Beerblock, K., Bouhier-Leporrier, K., Slimane Fawzi, K., Cany, L., Chone, L., Dahan, L., Gasnault, L., Rob, L., Stefani, L., Wander, L., Baconnier, M., Ben Abdelghani, M., Benchalal, M., Blasquez, M., Carreiro, M., Charbit, M., Combe, M., Duluc, M., Fayolle, M., Gignoux, M., Giovannini, M., Glikmanas, M., Mabro, M., Mignot, M., Mornet, M., Mousseau, M., Mozer, M., Pauwels, M., Pelletier, M., Porneuf, M., Ramdani, M., Schnee, M., Tissot, M., Zawadi, M., Clavero-Fabri, M.C., Gouttebel, M.C., Kaminsky, M.C., Galais, M.P., Abdelli, N., Barrière, N., Bouaria, N., Bouarioua, N., Delas, N., Gérardin, N., Hess-Laurens, N., Stremsdoerfer, N., Berthelet, O., Boulat, O., Capitain, O., Favre, O., Amoyal, P., Bergerault, P., Burtin, P., Cassan, P., Chatrenet, P., Chiappa, P., Claudé, P., Couzigou, P., Feydy, P., Follana, P., Geoffroy, P., Godeau, P., Hammel, P., Laplaige, P., Lehair, P., Martin, P., Novello, P., Pantioni, P., Pienkowski, P., Pouderoux, P., Prost, P., Ruszniewski, P., Souillac, P., Texereau, P., Thévenet, P., Haineaux, P.A., Benoit, R., Coriat, R., Lamy, R., Mackiewicz, R., Beorchia, S., Chaussade, S., Hiret, S., Jacquot, S., Lavau Denes, S., Montembault, S., Nahon, S., Nasca, S., Nguyen, S., Oddou-Lagraniere, S., Pesque-Penaud, S., Fratte, S.P., Chatellier, T., Mansourbakht, T., Morin, T., Walter, T., Boige, V., Bourgeois, V., Derias, V., Guérin-Meyer, V., Hautefeuille, V., Jestin Le Tallec, V., Lorgis, V., Quentin, V., Sebbagh, V., Veuillez, V., Adhoute, X., Coulaud, X., Becouarn, Y., Coscas, Y., Courouble, Y., Le Bricquir, Y., Molin, Y., Rinaldi, Y., Lam, Y.H., Ladhib, Z., Aparicio, Thomas, Ducreux, Michel, Faroux, Roger, Barbier, Emilie, Manfredi, Sylvain, Lecomte, Thierry, Etienne, Pierre-Luc, Bedenne, Laurent, Bennouna, Jaafar, Phelip, Jean-Marc, François, Eric, Michel, Pierre, Legoux, Jean-Louis, Gasmi, Mohamed, Breysacher, Gilles, Rougier, Philippe, De Gramont, Aimery, Lepage, Come, Bouché, Olivier, and Seitz, Jean-François

Published
2018
Full Text
View/download PDF

27. Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effects

Author

Pernot, Simon, Badoual, Cecile, Terme, Magali, Castan, Florence, Cazes, Aurelie, Bouche, Olivier, Bennouna, Jaafar, Francois, Eric, Ghiringhelli, Francois, De La Fouchardiere, Christelle, Samalin, Emmanuelle, Bachet, Jean Baptiste, Borg, Christophe, Ducreux, Michel, Marcheteau, Elie, Stanbury, Trevor, Gourgou, Sophie, Malka, David, and Taieb, Julien

Published
2017
Full Text
View/download PDF

34. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial

Author

Conroy, Thierry, Galais, Marie-Pierre, Raoul, Jean-Luc, Bouché, Olivier, Gourgou-Bourgade, Sophie, Douillard, Jean-Yves, Etienne, Pierre-Luc, Boige, Valérie, Martel-Lafay, Isabelle, Michel, Pierre, Llacer-Moscardo, Carmen, François, Eric, Créhange, Gilles, Abdelghani, Meher Ben, Juzyna, Beata, Bedenne, Laurent, and Adenis, Antoine

Published
2014
Full Text
View/download PDF

44. Targeting HGF/c-Met Axis Decreases Circulating Regulatory T Cells Accumulation in Gastric Cancer Patients

Author

Palle, Juliette, Hirsch, Laure, Lapeyre-Prost, Alexandra, Malka, David, Bourhis, Morgane, Pernot, Simon, Marcheteau, Elie, Voron, Thibault, Castan, Florence, Lacotte, Ariane, Benhamouda, Nadine, Tanchot, Corinne, François, Eric, Ghiringhelli, François, de la Fouchardière, Christelle, Zaanan, Aziz, Tartour, Eric, Taieb, Julien, Terme, Magali, Paris-Centre de Recherche Cardiovasculaire (PARCC (UMR_S 970/ U970)), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Département de Médecine Oncologique, Gustave Roussy, Université Paris-Saclay, Biostatistics Unit, CTD INCa, ICM-Montpellier Cancer Institute, Centre de Lutte contre le Cancer Antoine Lacassagne [Nice] (UNICANCER/CAL), UNICANCER-Université Côte d'Azur (UCA), Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER, Medical Oncology Department, Centre Léon Bérard, Lyon, Department of Gastrointestinal Oncology, AP-HP, HEGP, Université de Paris, and TERME, Magali

Subjects
[SDV.IMM] Life Sciences [q-bio]/Immunology, [SDV]Life Sciences [q-bio], gastric cancer, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, [SDV.CAN]Life Sciences [q-bio]/Cancer, Article, regulatory T cells, targeted therapies, [SDV] Life Sciences [q-bio], hepatocyte growth factor, [SDV.CAN] Life Sciences [q-bio]/Cancer, [SDV.IMM]Life Sciences [q-bio]/Immunology, pro-angiogenic factor, anti-HGF, RC254-282, c-Met
Abstract

Simple Summary Restoring an effective immune response is the key goal of immunotherapy. One of the major mechanisms of tumor-induced immunosuppression is regulatory T cells (Treg) accumulation. In this study, using in vitro and in vivo analysis, we assessed the impact of the HGF/c-Met pathway, involved notably in tumor angiogenesis, on Treg accumulation in patients with gastric cancer. First, we reported that c-Met is expressed on circulating monocytes of gastric cancer patients and this expression seems to be associated with the worst outcome. Secondly, during in vitro cultures, c-Met+ monocytes differentiate into dendritic cells with tolerogenic properties able to induce the proliferation of Treg. Finally, rilotumumab, an anti-HGF antibody, decreases the percentage of circulating Treg in gastric cancer patients. Using HGF/c-Met inhibitors to partially reverse immunosuppression could lead to the development of new treatment associations, for example with immune checkpoint blockers. Abstract Elucidating mechanisms involved in tumor-induced immunosuppression is of great interest since it could help to improve cancer immunotherapy efficacy. Here we show that Hepatocyte Growth Factor (HGF), a pro-tumoral and proangiogenic factor, and its receptor c-Met are involved in regulatory T cells (Treg) accumulation in the peripheral blood of gastric cancer (GC) patients. We observed that c-Met is expressed on circulating monocytes from GC patients. The elevated expression on monocytes is associated with clinical parameters linked to an aggressive disease phenotype and correlates with a worse prognosis. Monocyte-derived dendritic cells from GC patients differentiated in the presence of HGF adopt a regulatory phenotype with a lower expression of co-stimulatory molecules, impaired maturation capacities, and an increased ability to produce interleukin-10 and to induce Treg differentiation in vitro. In the MEGA-ACCORD20-PRODIGE17 trial, GC patients received an anti-HGF antibody treatment (rilotumumab), which had been described to have an anti-angiogenic activity by decreasing proliferation of endothelial cells and tube formation. Rilotumumab decreased circulating Treg in GC patients. Thus, we identified that HGF indirectly triggers Treg accumulation via c-Met-expressing monocytes in the peripheral blood of GC patients. Our study provides arguments for potential alternative use of HGF/c-Met targeted therapies based on their immunomodulatory properties which could lead to the development of new therapeutic associations in cancer patients, for example with immune checkpoint inhibitors.

Published
2021

45. Predictive value of vascular endothelial growth factor polymorphisms for maintenance bevacizumab efficacy in metastatic colorectal cancer: an ancillary study of the PRODIGE 9 phase III trial.

Author

de Rauglaudre, Bernadette, Sibertin-Blanc, Camille, Fabre, Aurélie, Le Malicot, Karine, Bennouna, Jaafar, Ghiringhelli, François, Taïeb, Julien, Boige, Valérie, Bouché, Olivier, Chatellier, Thierry, Faroux, Roger, François, Eric, Jacquot, Stéphane, Genet, Dominique, Mulot, Claire, Olschwang, Sylviane, Seitz, Jean-François, Aparicio, Thomas, and Dahan, Laetitia

Abstract

Background: Several studies have reported the impact of single nucleotide polymorphisms (SNPs) in vascular endothelial growth factor (VEGF) pathway genes on the efficacy of bevacizumab in metastatic colorectal cancer (mCRC), but results are still inconsistent. The PRODIGE 9 phase III study compared bevacizumab maintenance versus observation alone after induction chemotherapy with FOLFIRI plus bevacizumab. Objective: We evaluated the impact of SNPs of VEGF-A, VEGF receptors (VEGFR-1, VEGFR-2), and hypoxia inducible factor-1α (HIF-1α) on tumor control duration (TCD), overall survival (OS), progression-free survival (PFS), and duration of first chemotherapy free-intervals (CFI). Patients and methods: We included 314/491 patients from PRODIGE 9 with a DNA blood sample available. Nine SNPs were genotyped on germline DNA using real-time Polymerase Chain Reaction TaqMan TM (Thermo Fisher Scientific, Waltham, MA, USA 02451). Results: In the bevacizumab arm, patients with the VEGFR-1 rs9582036 CC genotype (n = 14) had significantly longer TCD [22.4 months (95% confidence interval (CI): 14.75-not reached)] than patients with the AA or CA genotype [14.4 months (95% CI: 11.7–17.1)] (p = 0.036), whereas there was no significant difference in the observation arm. In the bevacizumab arm, no significant difference was found between the CC, and AA or CA genotype for OS [28.2 (95% CI: 18.1–42.8) versus 22.5 (95% CI: 18.6–24.6) months, p = 0.5], PFS [9.4 (95% CI: 7.2–11.3) versus 9.2 (95% CI: 8.71–10.1)], and duration of the first CFI [4.6 (95% CI: 1.6–13.3) versus 4.14 (95% CI: 0.5–29.0) months, p = 0.3]. Conclusion: Among mCRC patients treated with bevacizumab maintenance, those with the VEGFR-1 rs9582036 CC genotype experienced longer TCD. The presence of this genotype may thus predict a benefit of bevacizumab maintenance in mCRC. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

50. SOCRATE-PRODIGE 55 trial: A randomized phase II study to evaluate second-line ramucirumab alone or with paclitaxel in older patients with advanced gastric cancer.

Author

Boisteau, Emeric, François, Eric, Aparicio, Thomas, Le Malicot, Karine, Boulahssass, Rabia, Lecomte, Thierry, Laurent-Puig, Pierre, Guiu, Boris, Paillaud, Elena, Galais, Marie-Pierre, Lopez-Trabada Ataz, Daniel, Tougeron, David, Dourthe, Louis-Marie, Guimbaud, Rosine, Samalin, Emmanuelle, Moreau, Marie, Louvet, Christophe, Lepage, Côme, and Lièvre, Astrid

Abstract

Patients ≥ 70 years old constitute 40% of patients with advanced gastric cancer (GC). Ramucirumab plus Paclitaxel is a therapeutic option validated in the second-line treatment of advanced GC, but as older patients are at higher risk of severe toxicity, due to comorbidities and/or frailty, we aimed to evaluate second-line Ramucirumab alone or combined with Paclitaxel in terms of overall survival (OS) and quality of life (QoL) in patients ≥ 70 years-old with advanced GC. In this multicenter, randomized, open-label, non-comparative, prospective phase II clinical trial, the main inclusion criteria are: patients ≥ 70 years old, with advanced GC having progressed after first-line chemotherapy or in the six months following the last administration of adjuvant chemotherapy, with WHO performance status <2. They are randomized to receive either ramucirumab alone (arm A) or ramucirumab plus Paclitaxel (arm B). The primary endpoint is 6-month OS and QoL evaluated with the EORTC QLQ-ELD14 questionnaire. The secondary endpoints include other parameters of QoL, time to definitive deterioration (TTDD) in QoL and TTDD in autonomy, treatment toxicities, other parameters of survival and disease control, identification of geriatric and nutritional prognostic scores and predictive factors of treatment safety and efficacy. OS of 60% is expected at 6 months (H0:40%). Using a Simon-minimax design, with one-sided α risk of 2% and 80% power for OS, and considering 5% lost to follow-up, it is necessary to randomize 56 patients in each arm. As older patients are at higher risk of chemotherapy toxicity, ramucirumab alone could be an interesting alternative to Paclitaxel plus ramucirumab, as a second-line therapy for patients ≥ 70 years old with advanced GC, and needs to be evaluated. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results